Actavis plc (NYSE:ACT) Keeps Its Phase Iii Promise With Molecular Partners’ Eye Drug

Actavis plc (NYSE:ACT) is on track with maintaining its promise to Allergan, Inc. (NYSE:AGN) through the upcoming introduction of phase III trials for abicipar. The drug is licensed by Sweden-based Molecular Partners. The drug is the first of the projects that have a direct influence on the $66 million merger. Ambicipar is a promising drug […]